Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bromocriptine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 known ✓ | P35462 | 5/20 | 1.00 |
| ▸ | DRD2 known ✓ | P14416 | 4/20 | 1.00 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 1.00 |
| ▸ | MAPT | P10636 | 10/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 9/20 | 1.00 |
| ▸ | MEN1 | O00255 | 8/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 8/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 7/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 5/20 | 1.00 |
| ▸ | DRD1 | P21728 | 5/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 4/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 4/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 4/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 4/20 | 1.00 |
| ▸ | HTR2A | P28223 | 4/20 | 1.00 |
| ▸ | HTR2C | P28335 | 4/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromocriptine SCHEMBL29414631 | 1.00 | KDM4E (1.00) | KDM4EMAPTCYP3A4MEN1KMT2A | |
| Bromocriptine SCHEMBL29364057 | 1.00 | KDM4E (1.00) | KDM4EMAPTCYP3A4MEN1KMT2A | |
| Bromocriptine SCHEMBL8032620 | 1.00 | KDM4E (1.00) | KDM4EMAPTCYP3A4MEN1KMT2A | |
| Bromocriptine SCHEMBL19276395 | 1.00 | KDM4E (1.00) | KDM4EMAPTCYP3A4MEN1KMT2A | |
| Bromocriptine SCHEMBL9526627 | 1.00 | KDM4E (1.00) | KDM4EMAPTCYP3A4MEN1KMT2A | |
| Bromocriptine SCHEMBL23468147 | 1.00 | KDM4E (1.00) | KDM4EMAPTCYP3A4MEN1KMT2A | |
| Bromocriptine SCHEMBL3134319 | 1.00 | KDM4E (1.00) | KDM4EMAPTCYP3A4MEN1KMT2A | |
| Bromocriptine SCHEMBL3134317 | 1.00 | KDM4E (1.00) | KDM4EMAPTCYP3A4MEN1KMT2A | |
| Bromocriptine SCHEMBL25297 | 1.00 | KDM4E (1.00) | KDM4EMAPTCYP3A4MEN1KMT2A | |
| Bromocriptine SCHEMBL11890530 | 1.00 | KDM4E (1.00) | KDM4EMAPTCYP3A4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11045464-B2 | Parenteral formulations of dopamine agonists | VEROSCIENCE LLC (US) | 2021-06-29 | — | — | US | claimed |
| US-20160324848-A1 | Parenteral Formulations Of Dopamine Agonists | VEROSCIENCE, LLC | 2016-11-10 | — | — | US | claimed |
| US-20130197005-A1 | Parenteral Formulations Of Dopamine Agonists | VEROSCIENCE LLC (US) | 2013-08-01 | — | — | US | claimed |
| EP-3038614-A1 | COMPOSITION COMPRISING TORASEMIDE AND BACLOFEN FOR TREATING NEUROLOGICAL DISORDERS | Pharnext (FR) | 2016-07-06 | — | — | EP | disclosed |
| EP-2892519-A1 | NOOTROPIC COMPOSITIONS FOR IMPROVING MEMORY PERFORMANCE | Pharnext (FR) | 2015-07-15 | — | — | EP | disclosed |
| WO-2015028659-A1 | COMPOSITION COMPRISING TORASEMIDE AND BACLOFEN FOR TREATING NEUROLOGICAL DISORDERS | PHARNEXT (FR) | 2015-03-05 | — | — | WO | disclosed |
| WO-2014037412-A1 | NOOTROPIC COMPOSITIONS FOR IMPROVING MEMORY PERFORMANCE | PHARNEXT (FR) | 2014-03-13 | — | — | WO | disclosed |
| EP-2560631-A2 | BACLOFEN AND ACAMPROSATE BASED THERAPY OF NEUROGICAL DISORDERS | Pharnext (FR) | 2013-02-27 | — | — | EP | disclosed |
| WO-2012117076-A2 | BACLOFEN AND ACAMPROSATE BASED THERAPY OF NEUROGICAL DISORDERS | PHARNEXT (FR) | 2012-09-07 | — | — | WO | disclosed |
| EP-2400955-A1 | METHODS OF ADMINISTERING (4AR, 1OAR)-I-N-PROPYL-I, 2,3,4A7 S1IO7 IOA-OCTAHYDROBENZO ÝG¨QUINOLINE-6,7-DIOL AND RELATED COMPOUNDS ACROSS THE ORAL MUCOSA, THE NASAL MUCOSA OR THE SKIN AND PHARMACEUTICAL COMPOSITIONS THEREOF | H. Lundbeck A/S (DK) | 2012-01-04 | — | — | EP | disclosed |
| EP-2252259-A2 | PARENTERAL FORMULATIONS OF DOPAMINE AGONISTS | VeroScience LLC (US) | 2010-11-24 | — | — | EP | disclosed |
| WO-2010097091-A1 | METHODS OF ADMINISTERING (4AR, 1OAR)-I-N-PROPYL-I, 2,3,4A7 S1IO7 IOA-OCTAHYDROBENZO [G] QUINOLINE-6,7-DIOL AND RELATED COMPOUNDS ACROSS THE ORAL MUCOSA, THE NASAL MUCOSA OR THE SKIN AND PHARMACEUTICAL COMPOSITIONS THEREOF | H. LUNDBECK A/S (DK) | 2010-09-02 | — | — | WO | disclosed |
| WO-2009091576-A2 | PARENTERAL FORMULATIONS OF DOPAMINE AGONISTS | VEROSCIENCE, LLC (US) | 2009-07-23 | — | — | WO | disclosed |